FGI-104

FGI-104

Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)-6-[4-(hydroxymethyl)-3-methoxyphenyl]phenol
PubChem CID	44158960
ChemSpider	65322076
CompTox Dashboard (EPA)	DTXSID201028023
Chemical and physical data
Formula	C28H30ClN3O3
Molar mass	492.02 g·mol−1
3D model (JSmol)	Interactive image
SMILES c4cnc1cc(Cl)ccc1c4Nc(cc2CN(CC)CC)cc(c2O)-c(cc3OC)ccc3CO
InChI InChI=1S/C28H30ClN3O3/c1-4-32(5-2)16-20-12-22(31-25-10-11-30-26-14-21(29)8-9-23(25)26)15-24(28(20)34)18-6-7-19(17-33)27(13-18)35-3/h6-15,33-34H,4-5,16-17H2,1-3H3,(H,30,31) Key:OFXBJOIYAJBMNY-UHFFFAOYSA-N

FGI-104 is the name of an experimental broad-spectrum antiviral drug, with activity against a range of viruses including hepatitis B, hepatitis C, HIV, Ebola virus, and Venezuelan equine encephalitis virus. ^[1]

Mechanism

The drug acts by inhibiting the protein TSG101, which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice from Ebola virus disease. ^{[2] [3]}

See also

• FGI-103
• FGI-106
• LJ-001

References

1. Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, et al. (January 2009). "FGI-104: a broad-spectrum small molecule inhibitor of viral infection". American Journal of Translational Research. 1 (1): 87–98. doi:10.1016/j.antiviral.2009.02.082. PMC   2776286 . PMID   19966942.
2. Janeba Z (November 2015). "Development of Small-Molecule Antivirals for Ebola". Medicinal Research Reviews. 35 (6): 1175–94. doi:10.1002/med.21355. PMC   7168439 . PMID   26172225.
3. Saxena A, Ferri M (2015). "Clinical Management of Ebola Virus Disease: Current and Future Approaches". In Saxena A (ed.). Communicable Diseases of the Developing World. Topics in Medicinal Chemistry. Vol. 29. Cham: Springer. pp. 1–36. doi:10.1007/7355_2015_5003. ISBN   978-3-319-78252-2.